Zarif Mohamed Sofian

Dr. Zarif Mohamed Sofian


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2021 in Polymers
Verified
Journal Article
Open access
PDF file
DRDANIA ADILA AHMAD RUZAIDI
DANIA ADILA AHMAD RUZAIDI
MMMohd Muzamir Mahat
Mohd Muzamir Mahat
ZSZarif Mohamed Sofian
Zarif Mohamed Sofian
NHNikman Adli Nor Hashim
Nikman Adli Nor Hashim
HOHazwanee Osman
Hazwanee Osman
HHHairul Hisham Hamzah
Hairul Hisham Hamzah
Herein we report the synthesis and characterization of electro-conductive chitosan–gelatin–agar (Cs-Gel-Agar) based PEDOT: PSS hydrogels for tissue engineering. Cs-Gel-Agar porous hydrogels with 0–2.0% (v/v) PEDOT: PSS were fabricated using a thermal reverse casting method where low melting agarose served as the pore template. Sample characterizations were performed by means of scanning electron microscopy (SEM), attenuated total reflectance–Fourier transform infrared spectroscopy (ATR–FTIR), X-ray diffraction analysis (XRD) and electrochemical impedance spectroscopy (EIS). Our results showed enhanced electrical conductivity of the cs-gel-agar hydrogels when mixed with DMSO-doped PEDOT: PSS wherein the optimum mixing ratio was observed at 1% (v/v) with a conductivity value of 3.35 × 10−4 S cm−1. However, increasing the PEDOT: PSS content up to 1.5 % (v/v) resulted in reduced conductivity to 3.28 × 10−4 S cm−1. We conducted in vitro stability tests on the porous hydrogels using phosphate-buffered saline (PBS) solution and investigated the hydrogels’ performances through physical observations and ATR–FTIR characterization. The present study provides promising preliminary data on the potential use of Cs-Gel-Agar-based PEDOT: PSS hydrogel for tissue engineering, and these, hence, warrant further investigation to assess their capability as biocompatible scaffolds.

27 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RKRamsha Khalid
Ramsha Khalid
SMsyed mahmood
syed mahmood
ZSZarif Mohamed Sofian
Zarif Mohamed Sofian
AHAyah Rebhi Hilles
Ayah Rebhi Hilles
NHNajihah Hashim
Najihah Hashim
YGYi Ge
Yi Ge
One of the most cutting-edge, effective, and least invasive pharmaceutical innovations is the utilization of microneedles (MNs) for drug delivery, patient monitoring, diagnostics, medicine or vaccine delivery, and other medical procedures (e.g., intradermal vaccination, allergy testing, dermatology, and blood sampling). The MN-based system offers many advantages, such as minimal cost, high medical effectiveness, comparatively good safety, and painless drug application. Drug delivery through MNs can possibly be viewed as a viable instrument for various macromolecules (e.g., proteins, peptides, and nucleic acids) that are not efficiently administered through traditional approaches. This review article provides an overview of MN-based research in the transdermal delivery of hypertensive drugs. The critical attributes of microneedles are discussed, including the mechanism of drug release, pharmacokinetics, fabrication techniques, therapeutic applications, and upcoming challenges. Furthermore, the therapeutic perspective and improved bioavailability of hypertensive drugs that are poorly aqueous-soluble are also discussed. This focused review provides an overview of reported studies and the recent progress of MN-based delivery of hypertensive drugs, paving the way for future pharmaceutical uses. As MN-based drug administration bypasses first-pass metabolism and the high variability in drug plasma levels, it has grown significantly more important for systemic therapy. In conclusion, MN-based drug delivery of hypertensive drugs for increasing bioavailability and patient compliance could support a new trend of hypertensive drug delivery and provide an alternative option, overcoming the restrictions of the current dosage forms.

2 October 2021 in Polymers
Verified
Journal Article
Open access
PDF file
DRDANIA ADILA AHMAD RUZAIDI
DANIA ADILA AHMAD RUZAIDI
MMMohd Muzamir Mahat
Mohd Muzamir Mahat
SSSaiful Arifin Shafiee
Saiful Arifin Shafiee
ZSZarif Mohamed Sofian
Zarif Mohamed Sofian
Awis Sukarni Mohmad SabereAwis Sukarni Mohmad Sabere
Awis Sukarni Mohmad Sabere
Kishor Kumar SadasivuniKishor Kumar Sadasivuni
Kishor Kumar Sadasivuni
Scaffolds support and promote the formation of new functional tissues through cellular interactions with living cells. Various types of scaffolds have found their way into biomedical science, particularly in tissue engineering. Scaffolds with a superior tissue regenerative capacity must be biocompatible and biodegradable, and must possess excellent functionality and bioactivity. The different polymers that are used in fabricating scaffolds can influence these parameters. Polysaccharide-based polymers, such as collagen and chitosan, exhibit exceptional biocompatibility and biodegradability, while the degradability of synthetic polymers can be improved using chemical modifications. However, these modifications require multiple steps of chemical reactions to be carried out, which could potentially compromise the end product’s biosafety. At present, conducting polymers, such as poly(3,4-ethylenedioxythiophene) poly(4-styrenesulfonate) (PEDOT: PSS), polyaniline, and polypyrrole, are often incorporated into matrix scaffolds to produce electrically conductive scaffold composites. However, this will reduce the biodegradability rate of scaffolds and, therefore, agitate their biocompatibility. This article discusses the current trends in fabricating electrically conductive scaffolds, and provides some insight regarding how their immunogenicity performance can be interlinked with their physical and biodegradability properties.

30 May 2025 in Molecules
Verified
Journal Article
Open access
PDF file
YCYong Li Chan
Yong Li Chan
RWRiyanto Teguh Widodo
Riyanto Teguh Widodo
Long MingLong Ming
Long Ming
AKAbdullah Khan
Abdullah Khan
SASyed Atif Abbas
Syed Atif Abbas
MKMahibub Muhamadsa Muhamadsa Kanakal
Mahibub Muhamadsa Muhamadsa Kanakal
Three-dimensional printing, particularly Fused Deposition Modeling (FDM), has revolutionized dermatological drug delivery by offering the ability to create personalized and precise drug formulations. This technology enables the design of customized drug delivery systems using a variety of polymers, such as Polylactic Acid (PLA), Polyvinyl Alcohol (PVA), Polyethylene Glycol (PEG), and Polycaprolactone (PCL), each with unique properties that enhance drug release, patient compliance, and treatment efficacy. This review analyzes these polymers in terms of their advantages, limitations, and suitability for dermatological applications. The ability to tailor these materials offers significant potential in overcoming treatment regimens. Additionally, the customization of three-dimensional-printed drug delivery systems provides a platform for creating patient-specific solutions that are more effective and adaptable to individual needs. Despite challenges such as moisture sensitivity and mechanical brittleness, the potential of FDM technology to improve dermatological treatments remains promising. The future of three-dimensional printing in dermatology lies in the integration of optimized materials and advanced printing techniques, which could further enhance patient-specific care and broaden the clinical applicability of these technologies in the pharmaceutical and biomedical sectors. By addressing these limitations and expanding material choices, FDM-based drug delivery systems have the potential to revolutionize the management of dermatological conditions, offering improved therapeutic outcomes and quality of life for patients.

7 April 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RKRamsha Khalid
Ramsha Khalid
SMsyed mahmood
syed mahmood
ZSZarif Mohamed Sofian
Zarif Mohamed Sofian
ZCzamri chik
zamri chik
YGYi Ge
Yi Ge
Background: Hypertension (HTN) is recognized as a major risk factor for cardiovascular disease, chronic kidney disease, and peripheral artery disease. Valsartan (VAL), an angiotensin receptor blocker drug for hypertension, has been limited due to its poor solubility and poor absorption from the GIT, which leads to low oral bioavailability. Objectives/Method: In the present research, firstly, VAL-loaded nanoliposomes were formulated and optimized using the Box–Behnken design (BBD). Optimized VAL-nanoliposomes were physically characterized and their fate was examined by scanning and transmission microscopy, DSC, FTIR, XRD, and ex vivo studies using rat skin. In vitro studies using human keratinocyte (HaCaT) cells showed a decrease in cell viability as the liposome concentration increased. Secondly, the formulation of VAL-loaded nanoliposomes was integrated into dissolvable microneedles (DMNs) to deliver the VAL transdermally, crossing the skin barrier for better systemic delivery. Results: The optimized nanoliposomes showed a vesicle size of 150.23 (0.47) nm, a ZP of −23.37 (0.50) mV, and an EE% of 94.72 (0.44)%. The DMNs were fabricated using a ratio of biodegradable polymers, sodium alginate (SA), and hydroxypropyl methylcellulose (HPMC). The resulting VAL-LP-DMNs exhibited sharp pyramidal microneedles, adequate mechanical properties, effective skin insertion capability, and rapid dissolution of the microneedles in rat skin. In the ex vivo analysis, the transdermal flux of VAL was significantly (5.36 (0.39) μg/cm2/h) improved by VAL-LP-DMNs. The enhancement ratio of the VAL-LP-DMNs was 1.85. In conclusion, liposomes combined with DMNs have shown high potential and bright prospects as carriers for the transdermal delivery of VAL. Conclusions: These DMNs can be explored in studies focused on in vivo evaluations to confirm their safety, pharmacokinetics profile, and pharmacodynamic efficacy.

31 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ISIqra Safdar
Iqra Safdar
SMsyed mahmood
syed mahmood
MAMuhammad Kumayl Abdulwahab
Muhammad Kumayl Abdulwahab
SNSuzita Noor
Suzita Noor
YGYi Ge
Yi Ge
ZSZarif Mohamed Sofian
Zarif Mohamed Sofian
Lung cancer remains one of the most common and deadliest forms of cancer worldwide despite notable advancements in its management. Conventional treatments, such as chemotherapy, often have limitations in effectively targeting cancer cells, which frequently lead to off-target side effects. In this context, the pulmonary delivery of inhalable nanomaterials offers the advantages of being rapid, efficient, and target-specific, with minimal systemic side effects. This concise review summarizes the basic research and clinical translation of inhalable nanomaterials for the treatment of lung cancer. We also provide insights into the latest advances in pulmonary drug delivery systems, focusing on various types of pulmonary devices and nanomaterials. Furthermore, this paper discusses significant challenges in translating the discoveries of inhalable nanomaterials into clinical care for lung cancer and shares strategies to overcome these issues.